Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Observational Study to Evaluate Disease Presentation and Progression in Subjects With ENPP1 Deficiency and the Early-Onset Form of ABCC6 Deficiency

NCT05050669 is registered in ClinicalTrials.gov with Inozyme Pharma as lead sponsor.

NCT NCT05050669
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05050669 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Observational Study to Evaluate Disease Presentation and Progression in Subjects With ENPP1 Deficiency and the Early-Onset Form of ABCC6 Deficiency
Lead sponsor
Inozyme Pharma
Phase
Observational
Overall status
Completed
Start date
June 28, 2022
Completion date
June 26, 2024
Enrollment
12 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

adenosine triphosphate binding cassette transporter protein subfamily c member 6, autosomal recessive hypophosphatemic rickets, ectonucleotide pyrophosphatase/phosphodiesterase1 deficiency, generalized arterial calcification of infancy